Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Linaprazan Glurate in Healthy Subjects
NCT05742984Phase 1Completed
- Sponsor
- Cinclus Pharma
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linaprazan glurate in gastroesophageal reflux disease (GERD) (6 arms), sponsored by Cinclus Pharma. Primary endpoints: Area Under the Curve from 0 to 24 hours (QD), Area Under the Curve from 0-12h and 12-24h (BID) at Day 14 and 2 more. Started Jan 2023; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05742984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742984.